Gilead Sciences Remains A Popular Biotech Stock Following Earnings
May 04, 2015 at 05:28 AM EDT
Gilead Sciences released first quarter 2015 earnings on April 30. High revenues pointed to the success of Gilead’s blockbuster hepatitis C therapies; Sovaldi and Harvoni.
